ClinicalTrials.gg
RecruitingNCT06735885Updated Jul 6, 2026

fMRI Neurofeedback With Matter Neuroscience App

An interventional study of Matter Neuroscience App and Stock Photos in Depression Mild, Depression and Depression Moderate, sponsored by Stanford University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Stanford University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 77 studies in Depression by Stanford University — 15 open to participants now, 17 under way, none of them phase 3. Depression · Stanford University.

Planned enrollment
5th of 64
240 · median 40
Started
2025
with 3 others
No phase
45 of 77
12 open now
Primary completion
2027-06
later than 6 of 16 live
Registered
68th of 77
by date

Among the 77 studies in Depression by Stanford University, this one is the 5th largest by planned enrollment of the 64 interventional ones that give a count, is one of 4 that started in 2025, is one of 45 with no phase, reaches primary completion later than 6 of the 16 other live ones, and was the 68th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

15 of the 77 studies in Depression by Stanford University are open now, in 2 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Depression by Stanford University, or all of them as a file.
02

Study summary

Study will utilize an app, Matter Neuroscience, designed to help users with depression understand positive emotions and the neurotransmitters that create them. We hope to learn the safety and efficacy of neurofeedback for treating depression and lay the groundwork for a pivotal clinical trial.

Read the detailed description

The Matter Neuroscience application, available through the Apple App Store, is designed to help users understand positive emotions and the neurotransmitters that create them. The application allows users to collect good moments by adding photos and other information to the application and activating positive emotions when the photos and other information are viewed. When positive emotions are activated, the application allows users to quickly rate the positive emotions felt during moments. The data collected is translated into the user's Matter Score. Tracking the user's Matter Score can allow them to see how they are doing from the inside out. Neurotransmitter activity helps build neuroplasticity in the brain. Higher levels of neuroplasticity correlate with higher levels of creativity, intelligence, and empathy as well as longer, healthier, happier lifespans. The 7TMRI Scanner will be used to gather structural and functional brain data.

03

Conditions studied

  • Depression Mild
  • Depression
  • Depression Moderate

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or Female, between the ages of 18 and 80 at the time of screening.
  2. Primary diagnosis of nonpsychotic major depressive disorder (MDD) without a history of psychotic features.
  3. Score on the MADRS scale between 15-25
  4. Able to read, understand, and provide written, dated prior to screening. Proficiency in English sufficient to complete questionnaires / follow instructions during fMRI. Stated willingness to comply with all study procedures, including availability for the duration of the study, and to communicate with study personnel about adverse events and other information.
  5. Must possess an iPhone with the latest iOS version compatible with the app or must be willing to use a loaner iPhone from the study if available.
  6. Has had at least one lifetime antidepressant treatment failure (ATHF)
  7. The dose of the primary antidepressant medication (if applicable) must be stable for 4 weeks prior to baseline, and participants must agree to continue at this dose throughout the study period.
  8. In good general health, as evidenced by medical history and determined by study physician
  9. For women of : agree to the use of highly effective during study participation.
  10. Adequate visual acuity (with or without corrective lenses) to view study materials while in the MRI.
  11. Agreement to adhere to Lifestyle Considerations throughout study duration.

Exclusion criteria

Exclusion Criteria:

  1. to MRI (ferromagnetic metal in their body)
  2. Severe claustrophobia
  3. Women that are pregnant or breastfeeding or with a positive urine pregnancy test at participation, or who are planning to become pregnant during the study period.
  4. Primary psychiatric condition other than MDD requiring treatment except stable comorbid anxiety disorder
  5. History of or current psychotic disorder, schizophrenia, psychosis, bipolar disorder, or severe borderline personality disorder.
  6. Diagnosis of intellectual disability, autism spectrum disorder, or other neurodevelopmental disorder.
  7. Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal
  8. Urine screening test positive for recent use of recreational drugs except for marijuana..
  9. Considered at significant risk for suicide during the course of the study.
  10. Recent (within 4 weeks of any clinical effect) or concurrent use of rapid acting antidepressant agent (i.e., a course of ECT or TMS). Excluding ketamine.
  11. History of significant neurologic disease, including dementia, Parkinson's or Huntington's disease, brain tumor, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma as determined by the PD.
  12. Untreated or insufficiently treated endocrine or metabolic disorder.
  13. Any other condition deemed by the PD to interfere with the study or increase risk to the participant
  14. Alexithymia as determined by the Toronto Alexithymia Scale
  15. Treatment with an drug or other intervention within the study period.
  16. Not currently in a major depressive episode as defined by the MINI.
  17. More than 5 lifetime adequate antidepressant medication failures (ATHF).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • No intervention
    Arm 1A. No home training, no neurofeedback, no photos, no repeated scans

    No home training, no neurofeedback, no photos, no repeated scans

  • Experimental
    Arm 1B. No home training no neurofeedback, repeated scans, personal photos

    No home training no neurofeedback, repeated scans, personal photos

    Device: Matter Neuroscience App · Other: No Home Training · Other: Personal Photos

  • Experimental
    Arm 2. No home training, neurofeedback, stock photos, repeated scans

    No home training, neurofeedback, stock photos, repeated scans

    Device: Matter Neuroscience App · Other: Stock Photos · Other: No Home Training

  • Experimental
    Arm 3. No home training, neurofeedback, personal photos, repeated scans

    No home training, neurofeedback, personal photos, repeated scans

    Device: Matter Neuroscience App · Other: No Home Training · Other: Personal Photos

  • Experimental
    Arm 4. Home training, no neurofeedback, stock photos, repeated scans

    Home training, no neurofeedback, stock photos, repeated scans

    Device: Matter Neuroscience App · Other: Stock Photos · Other: Home Training

  • Experimental
    Arm 5. Home training, neurofeedback, stock photos, repeated scans

    Home training, neurofeedback, stock photos, repeated scans

    Device: Matter Neuroscience App · Other: Stock Photos · Other: Home Training

  • Experimental
    Arm 6. Home training, no neurofeedback, personal photos, repeated scans

    Home training, no neurofeedback, personal photos, repeated scans

    Device: Matter Neuroscience App · Other: Personal Photos · Other: Home Training

  • Experimental
    Arm 7. Home training, neurofeedback, personal photos, repeated scans

    Home training, neurofeedback, personal photos, repeated scans

    Device: Matter Neuroscience App · Other: Personal Photos · Other: Home Training

Interventions

  • DeviceMatter Neuroscience App

    An iPhone smartphone application

  • OtherStock Photos

    Stock Photos

  • OtherNo Home Training

    No Home Training

  • OtherPersonal Photos

    Personal Photos

  • OtherHome Training

    Home Training

06

What researchers measure

Primary outcomes

  1. Determine the safety and efficacy of neurofeedback for treating depression through MADRS scale changes

    Determine the safety and efficacy of neurofeedback for treating depression through MADRS (Montgomery-Åsberg Depression Rating Scale) scale changes. The 9-item self-report version of the MADRS has an overall score range from 0-27, with higher scores corresponding to higher levels of depression.

    Time frame: Screening, Baseline, Immediate Post, One Month Post, Three Month and Optional Six Month

Secondary outcomes

  1. Measure fMRI Change

    Measure fMRI Change

    Time frame: Baseline, Week 2, Week 4, Week 6, Immediate Post, Optional Three Month Post Scan

07

Study locations

1 of 1 sites recruiting
  • Stanford University Brain Stimulation Lab
    Stanford, California 94304, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jun 2027, 22 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 22 months is close to that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2024
First posted
Dec 16, 2024
StartActual
Aug 12, 2025
Primary completionEst.
Jun 15, 2027
CompletionEst.
Jun 15, 2028
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06735885
Responsible party
David Spiegel (Professor and Associate Chair of Psychiatry & Behavioral Sciences, Stanford University) — Principal investigator
First posted
Dec 16, 2024
Start date
Aug 12, 2025
Primary completion
Jun 15, 2027 (estimated)
Completion
Jun 15, 2028 (estimated)
Last update
Jul 6, 2026

Study contacts

Stephanie Wan
Contact
stephwan@stanford.edu
650 491 6339
Nick Bassano
Contact
nbassano@stanford.edu
650-800-6920
David Spiegel, MD
principal investigator · Department of Psychiatry and Behavioral Sciences, Stanford School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion